P regnancy is a risk factor for venous thromboembolism (VTE) and the risk is highest in the postpartum period (1, 2). Anticoagulants are very effective in the prevention of pulmonary embolism (PE) and recurrent thrombosis, but the treatment of deep vein thrombosis (DVT) remains a challenge, because lysis of the thrombus formed in the deep veins is slow and frequently inadequate as a therapy (3, 4). Complete or significant lysis occurs only in 4% of patients treated with heparin alone (3). Persistence of thrombus within deep veins leads to venous hypertension, which is ultimately the cause of post-thrombotic syndrome (PTS) and late disability in 20% to 50% of patients. PTS is a conglomerate of lifestyle-limiting symptoms that commonly includes chronic leg pain and swelling, heaviness, and/or fatigue, venous claudication, stasis dermatitis, and in advanced cases skin ulcerations due to valvular incompetence accompanied by persistent venous outflow obstruction (4-8). Pregnant women are generally younger than other women in the general population, and they likely suffer a more severe form of PTS for a much longer time.Anticoagulants have been the standard therapy of DVT in pregnant women because of concerns related to administering contrast agent, exposing the fetus to radiation during interventional radiologic procedures, and bleeding complication associated with thrombolysis (9). Nonetheless, there are a few publications describing thrombolytic therapy of DVT with good success during pregnancy and peri-or postpartum period (10-13). In a previous study (14), a pregnant woman with DVT was treated using percutaneous mechanical thrombectomy under venographic guidance with contrast agent. Percutaneous aspiration thrombectomy (PAT) with or without fluoroscopy guidance in preg-
71From the Department of Radiology (M.G.